The brochure with 'safe for all skin types' written across the top
On a Thursday in March 2024, a partner clinic's marketing team sent over a draft brochure for brand review. It read: "Thermage is safe for all skin types, including sensitive skin. Zero downtime. Results are permanent."
I circled three words on the printout with a yellow marker: safe, zero, permanent.
Then I pulled up my email and typed a question that would've made the sales team groan.
I've worked in quality and brand compliance at Solta Medical since 2017. By the time this brochure landed in my inbox, we'd been part of Valeant Pharmaceuticals—which renamed itself Bausch Health in 2018—for about four years. If you're searching for "Solta Medical stock" today, there isn't one. The company was public from 2009 to 2013, then acquired in December 2013. So there's no NYSE ticker to check. (If someone tries to sell you one, it's not real.)
What does exist is a review queue. On average, my team and I process roughly 200 marketing assets a year—brochures, clinical scripts, social posts, training decks. In rounds with first-time partners, I'll reject somewhere around 60% of what comes in during the first pass. Most of it is small fixes. Sometimes it's structural.
This brochure was structural.
My first question was simple: where's the data?
I replied within 20 minutes: "Could you share the specific study or internal clinical assessment behind the 'safe for all skin types' claim, plus the 'zero downtime' and 'permanent results' language?"
The response came a day later: "This is standard industry phrasing. Our previous equipment partner approved similar copy."
I read it twice. I made myself a cup of coffee. I came back and read it a third time.
Six years ago, I would have signed off on it. That version of me—the one who'd been in the role for about eight months—assumed "standard industry phrasing" meant someone, somewhere, had checked it. Then we had a batch of 500 Fraxel brochures go out with a wrong wavelength printed in the product description. The number should have read 1550 nm. It read 1410 nm. Nobody caught it until a clinic called to ask why the marketing materials disagreed with the actual laser specs.
We had to pulp 500 pieces. Reprint cost us about $1,200. But the number that actually stung was the email from that clinic's practice manager: "We trusted your collateral enough to explain the technology to our patients. Now we look like we don't know our own equipment."
I spent the following weekend adding three rules to our review checklist:
- Check the claim against source data.
- Check the printed specs against the technical documentation.
- Check the print proof before it goes to layout.
Those three lines have traveled into every contract we've signed since. They've also come up in Solta Medical jobs postings—anyone applying for a quality or compliance role here should expect to hear about them at the first interview. When I applied back in 2017, I didn't think "reading marketing copy" would be the job. Here we are.
The afternoon I pulled the FDA database
With the brochure in question, I skipped straight to the source. The FDA's Center for Devices and Radiological Health (CDRH) has a public device database. I searched it that afternoon. Thermage's history goes back to 2002, when it received its first clearance for non-invasive improvement of periorbital wrinkles. Subsequent clearances extended coverage to facial wrinkles and skin tightening across additional body areas.
What the clearances do not say—anywhere—is "safe for all skin types" or "zero downtime" or "permanent."
Then I pulled out our own clinical training manual. The section on patient selection is not ambiguous. For sensitive or compromised skin, the protocol requires: reduced energy settings, longer cooling intervals, and a patch test before the full facial treatment. Sensitive skin isn't a contraindication. It's a modifier. Which means "safe for all skin types" isn't a simplification. It's a misrepresentation.
Same week, a similar issue surfaced with Clear+Brilliant Permea. A clinic reported a patient with two days of post-treatment redness. I checked the product documentation—Permea uses a 1927 nm wavelength with an enhanced drug-delivery mechanism designed to push topical actives deeper into the skin. For severely sensitized skin, that mechanism is a known irritation pathway. Not a defect. A boundary. The clinic had been reading the same brochure language we were now reviewing, and they'd applied the same "safe for everyone" assumption to a different product line.
Two products, one misconception: that a clinical device with proven efficacy is also universally safe in every context. It isn't. And I can't sign off on materials that pretend otherwise.
The phone call that nearly made me fold
The clinic's sales director called me on a Friday afternoon. Polite. Not aggressive. But clear.
"Look, we understand the diligence," she said. "But our competitors are printing this exact language. If our brochure reads more conservatively, patients are going to ask why we're hedging. That's a revenue conversation."
I told her I understood. Then I asked her to walk me through what happens if a patient with rosacea walks in, sees "safe for all skin types," books the treatment, and has a reaction. Who does she call? What does she tell the patient who says, "But your brochure said..."?
There was a long pause on her end. Then: "We've had that happen. Not with Thermage specifically. But it's happened."
Calculated the worst case during that pause—the clinic reposts the brochure, a patient files a complaint, the manufacturer's name gets attached to a claim we never approved. The upside for the clinic was maybe a bump in bookings. The downside was a brand liability that could reach back to us.
I didn't say any of that out loud. I just said: "Can we try one revision and see if it performs?"
What went back to them
We rewrote three sections:
- "Safe for all skin types" → "Suitability varies by skin type. Clinical assessment and patch testing are required before treatment."
- "Zero downtime" → "Most patients resume normal activities immediately. Mild redness may last 24–48 hours depending on skin sensitivity."
- "Permanent results" → "Results are typically maintained over multiple months. Longevity varies by individual skin condition and maintenance protocol."
To the revised copy, I attached two documents: the relevant pages from our clinical training manual (with the patient-selection modifier highlighted), and a link to the FDA device database entry for Thermage.
The clinic's marketing lead went quiet for two days. Then she called back with a different tone: "Honestly, we knew some of that language was a stretch. But no one had ever shown us the alternative in writing. It's easier to advertise vaguely when you don't have the source documents in front of you."
That's the part people don't talk about. Most of the pushback isn't malicious. It's just easier to repeat what everyone else is saying than to go find the primary source.
The three-month follow-up
We shipped the revised brochure to the clinic's three locations in late April 2024. Three months later, the marketing team sent me a short email: no complaints tied to "sensitive skin" or "results didn't last" language. What they did get: a patient who read the brochure and asked for a patch test before booking. The clinic's aesthetician said that had never happened before—patients usually asked for the treatment, not the test.
That's the outcome I didn't expect. The more conservative copy didn't stop bookings. It changed the kind of conversation patients started.
What I actually learned from saying no
I almost said yes. I want to be honest about that. For about half an hour on that Friday, I weighed the client relationship against a line of copy. The argument for approving it was "everyone does this." The argument against was "I don't have the data."
The second argument won. Not because I'm disciplined, but because I've been on the other side of it. The $1,200 reprint mistake, the clinic email that said "we look like we don't know our own equipment"—those experiences set a floor I won't drop below.
Here's what I tell new hires in my team when they ask how strict they should be:
You're not a rubber stamp. You're the last person between an unverified claim and a patient who believed it. Rejecting a brochure isn't obstruction. It's the reason a clinic can trust us with their reputation.
And the harder version of that: sometimes the right answer is "this isn't our strength." If a patient has severely compromised skin, Thermage or Fraxel may not be the right first step. A dermatologist-led assessment, a period of barrier repair, or a different treatment pathway might come first. Saying that out loud doesn't hurt the brand. It's what makes the brand worth listening to.
The brochure is still on my shelf, by the way—the original draft with three words circled in yellow. I keep it there to remind myself that "everyone else does it" is never a source document.
Leave a Reply